Abstract
This article evaluates New Zealand’s Medicines Amendment Bill 2011. This Bill is currently before Parliament and will amend the Medicines Act 1981. On June 20, 2011, the Australian and New Zealand governments announced their decision to proceed with a joint scheme for the regulation of therapeutic products such as medicines, medical devices, and new medical interventions. Eventually, the joint arrangements will be administered by a single regulatory agency: the Australia New Zealand Therapeutic Products Agency. The medicines regulations in Australia and New Zealand will be updated as part of this process. The Medicines Amendment Bill addresses some of the well-recognised deficiencies in the Medicines Act 1981. However, a comprehensive overhaul of the Act is not being undertaken. I argue that repealing and replacing the Medicines Act 1981 would be preferable and advisable, given the number of legal difficulties with the Act and, in particular, where it does not align with equivalent current international law.
Similar content being viewed by others
References
Australia New Zealand Therapeutic Products Agency (ANZTPA). No date. http://www.anztpa.org. Accessed May 1, 2012.
Australian Government. 2011. TGA reforms: A blueprint for TGA’s future. http://www.tga.gov.au/pdf/tga-reforms-blueprint.pdf.
Australian Senate. 2011. The regulatory standards for the approval of medical devices in Australia. Canberra: Community Affairs References Committee.
Department of Health and Ageing, Australian Government. 2010. Reforms in the medical devices regulatory framework: Discussion paper. http://www.tga.gov.au/pdf/consult/consult-devices-reforms-101130.pdf. Accessed May 25, 2012.
Department of Health and Ageing, Australian Government. 2011. Review to improve the transparency of the TGA: Final report. http://www.tga.gov.au/pdf/consult/review-tga-transparency-1101-final-report.pdf. Accessed May 25, 2012.
Food and Drug Administration (FDA). 2006. Performance report to Congress for Office of Combination Products. http://www.fda.gov/oc/combination/report2006/overview.html. Accessed April 14, 2012.
Food and Drug Administration (FDA). 2007. Nanotechnology: A report of the U.S. FDA Taskforce. http://www.fda.gov/nanotechnology/taskforce/report2007.pdf. Accessed April 14, 2012.
Harvey, K. 2011. TGA all bark no bite as Labor botches response to a series of reviews. The Conversation, December 8. http://theconversation.edu.au/tga-all-bark-no-bite-as-labor-botches-response-to-a-series-of-reviews-4640. Accessed April 14, 2012.
King, HC. 2011. Government to improve regulation of therapeutic goods. Media release, Parliamentary Secretary for Health and Ageing, December 8. http://www.health.gov.au/internet/ministers/publishing.nsf/Content/mr-yr11-ck-ck053.htm. Accessed May 25, 2012.
Levy, D., and T. Watkins. 2011. John Key addresses Australian Parliament. Stuff News NZ, June 20. http://www.stuff.co.nz/national/politics/5164763/John-Key-welcomed-to-Australian-Parliament. Accessed April 26, 2012.
McGettigan, J. 2009. New Zealand law’s protection of drug trial participants. Journal of Law and Medicine 16(5): 885–890.
Medsafe. 2012. Medical device recall actions: Metal-on-metal hip implants. http://medsafe.govt.nz/hot/RecallActionNoticesNew/MetalOnMetalHipImplants/MetalonMetalHipImplantsTimeline.asp. Accessed May 24, 2012.
Medsafe. No date. http://www.medsafe.govt.nz. Accessed April 27, 2012.
Metherell, M. 2011. Faulty hip implants: Senate inquiry wants action on “ticking time bomb.” The Sydney Morning Herald, November 23. http://www.smh.com.au/national/health/faulty-hip-implants-senate-inquiry-wants-action-on-ticking-time-bomb-20111122-1nsyc.html. Accessed May 24, 2012.
Ministry of Health. 1994. Medicines and medical devices: Discussion paper on the review of medicines legislation. Wellington, New Zealand.
Ministry of Health. 2011. Regulatory impact statement: Medicines Amendment Bill. http://www.health.govt.nz/about-ministry/legislation-and-regulation/regulatory-impact-statements/medicines-amendment-bill. Accessed April 28, 2012.
Moore, J. 2011. Is New Zealand’s regulation of nanomedical products adequate? Journal of Law and Medicine 19(1): 112–127.
New Zealand Association of Plastic Surgeons (NZAPS). Statement from NZAPS Re PIP breast implants. http://www.plasticsurgery.org.nz/news-and-events/pip-breast-implants-nzaps-media-release-26-april-2012. Accessed May 24, 2012.
New Zealand Parliamentary Debates (NZPD). 2012. Medicines Amendment Bill—first reading. New Zealand Parliamentary Debates (Hansard) 677: 602. http://www.parliament.nz/en-NZ/PB/Debates/Debates/6/4/3/50HansD_20120228_00000012-Medicines-Amendment-Bill-First-Reading.htm.
Peart, N., F. McCrimmon, and J. Dawson. 2003. Clinical trials. In The law of research, ed. J. Dawson and N. Peart, 175–195. Dunedin: University of Otago Press.
Therapeutic Goods Administration (TGA). 2012. PIP breast implants—TGA update. http://www.tga.gov.au/safety/alerts-device-breast-implants-pip-120518.htm. Accessed May 24, 2012.
Acknowledgments
I am very grateful to Dr. Robinson and Malcolm McDonald for their comments on earlier drafts. I also wish to thank the reviewers for their excellent comments.
Statement of Competing Interests and Funding Support
I am a New Zealand Law Society Health Law Committee member. The Committee made a submission on the Medicines Amendment Bill. The views expressed in this article are my own.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Moore, J. Proposed Changes to New Zealand’s Medicines Legislation in the Medicines Amendment Bill 2011. Bioethical Inquiry 10, 59–66 (2013). https://doi.org/10.1007/s11673-012-9413-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11673-012-9413-8